You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
達安基因(002030.SZ)2022年度預盈51億-58億元、同比增長40.95%-60.3%
格隆匯 02-01 21:29

格隆匯2月1日丨達安基因(002030.SZ)公佈,預計2022年度歸屬於上市公司股東的淨利潤51億元-58億元,同比增長40.95%-60.30%;扣除非經常性損益後的淨利潤49.3億元-56.3億元,同比增長39.38%-59.17%。

報吿期內,公司作為國內新冠核酸診斷產品的供應商之一,以自主開發、完整貫通的核酸檢測技術全產業鏈平台,啟動充足的產能提供新型冠狀病毒核酸檢測產品,全力保障市場供給,同時持續加強海外市場的開拓與佈局。市場對新型冠狀病毒(2019-nCoV)核酸檢測試劑盒及核酸檢測儀器、相關耗材的需求持續,對公司業績產生了積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account